Effect of food on the bioavailability of triclabendazole in patients with fascioliasis

British Journal of Clinical Pharmacology

Volumn 45, Issue 6, 1998, Pages 601-604

  Lecaillon, J B ^a   Godbillon, J ^a   Campestrini, J ^a   Naquira, C ^b   Miranda, L ^c   Pacheco, R ^c   Mull, R ^d   Poltera, A A ^e,f  

^a NOVARTIS PHARMA K K   (Japan)

^b Universidad Nacional Mayor de San Marcos   (Peru)

^c UNIVERSIDAD NACIONAL DE SAN ANTONIO ABAD DEL CUSCO   (Peru)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Serum and Impfinstitut   (Switzerland)

^f CIBA GEIGY LTD   (Switzerland)

Author keywords

Active metabolite; Bioavailability; Fasciola hepatica; Food; Kinetics; Patients

Indexed keywords

TRICLABENDAZOLE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; FASCIOLIASIS; FEMALE; FOOD DRUG INTERACTION; HUMAN; MALE; MEAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTHELMINTICS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CHILD; CROSS-OVER STUDIES; FASCIOLIASIS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 0031812756     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00725.x     Document Type: Article

References (13)

1. Bennett JL, Kohler P. Fasciola hepatica: Action in vitro of triclabendazole on immature and adult stages. Experimental Parasitology 1987; 63: 49-57.
2. Robinson CP. Triclabendazole. Drugs Today 1985; 21: 227-233.
3. Chen MG, Mott KF. Progress in assessment of the morbidity due to Fasciola hepatica infection: A review of the recent literature. Trop Dis Bull 1990; 87: R1-R38.
4. Loutan L, Bouvier M, Rojanawisut B, et al. Single treatment of invasive Fascioliasis with triclabendazole. Lancet 1989; 8659: 383.
5. Ripert C, Couprie B, Moyou R, Gaillard F, Appriou M, Tribouley-Duret J. Therapeutic effect of triclabendazole in patients with paragonimiasis in Cameroon: a pilot study. Transac Roy Soc Trop Med Hyg 1992; 86: 417.
6. Calvopiña M, Paredes W, Guderian RH, Poltera AA. Eficacia del triclabendazole en Paragonimiasis pulmonar humana refractaria a la emetina, bithionol y praziquantel. Parasitología al Dia 1993; 17: 44-46.
7. Rouan MC, Le Duigou F, Campestrini J, Lecaillon JB, Godbillon J. Fast liquid chromatography for the determination of drugs in plasma and combination with liquid-solid extraction in a fully automated system. J Chromatogr 1992; 573: 59-64.
8. Bolton S. Pharmaceutical statistics, 2nd (ed.) New York: Marcel Dekker, 1990; chapter 11.
9. Hennessy DR, Lacey H, Steel JW, Prichard RK. The kinetics of triclabendazole disposition in sheep. J Vet Pharmacol Therap 1987; 10: 64-72.
10. Toothaker RD, Welling PG. The effect of food on drug bioavailability. Ann Rev Pharmacol Toxicol 1980; 20: 173-199.
11. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988; 34: 315-317.
12. Welling PG. Influence of food and diet on gastrointestinal drug absorption. A review. J Pharmacokin Biopharm 1977; 5: 291-334.
13. Lecaillon JB, Dubois JB, Soula G, Poltera AA. Influence of food on the pharmacokinetics of CGP 6140 after oral administration ot a 1200 ing single dose to onchocerciasis patients. Br J Clin Pharmacol 1990; 30: 629-633.